Medexus Pharmaceuticals Inc (CVE:MDP) (OTCQX:MEDXF) (FRA:P731) CEO Ken d’Entremont tells Proactive its second quarter revenue rose to C$23.6 million from C$16.4 million during the same period last year, which it attributed mainly to its acquisition of IXINITY, as well as solid performances from key products.
d’Entremont says the specialty pharmaceutical company also reported that adjusted EBITDA for the period increased to C$3.0 million from C$0.5 million a year earlier, while swinging to an operating profit of C$0.6 million from a loss of $1.3 million in second quarter 2019.
